Many patients soon to be forced to switch obesity drug, NYT says

Many Americans will soon be forced by their health insurance to switch from one obesity drug to another that produces less weight loss, Rebecca Robbins and Reed Abelson of The New York Times reports. CVS Health’s (CVS) Caremark made the decision to exclude Eli Lilly’s (LLY) Zepbound from its coverage in spite of research that found it resulted in more weight loss than Novo Nordisk’s (NVO) Wegovy, which will still be covered.